Study will assess adult participants for gum disease and bacteria in the mouth. The dental exams are the same exams that normally take place in dentist’s office. Saliva and plaque will be collected from participants. Visits will be every 2 weeks or every month. Study lasts 10-12 months. Read More
At least 25 years old
At least sixteen (16) teeth
To be determined at Screening Visit: Presence of at least 4 sites (anterior or posterior) with probing pocket depths (PD) > 5 mm and < 6 mm and concomitant clinical attachment loss.
To be determined by testing subgingival plaque after the Screening Visit: Have detectable Pg in subgingival plaque as assessed by PCR (we will take sampl...
Participants will be asked questions about a new cognitive processing test (how fast they can think). This study involves a single visit which takes about 20-minutes at the Conventus Medical Center in Buffalo. 50 multiple sclerosis patients and 50 healthy people will be enrolled. Read More
Physician established diagnosis of multiple sclerosis
18 years of age or older
Able to read and speak English
Study to evaluate reducing worry, anxiety, and stress in underserved communities highly impacted by the COVID-19 pandemic. Mindfulness Based Stress Reduction programs (meditation, breathing and movement) will be delivered via video / teleconference or a smart phone APP. The study lasts approximately 21 weeks. Read More
(1) age 18 years and older
(2) a baseline score ≥26 (clinically significant worry) on the Penn State Worry Questionnaire-Abbreviated
(3) fluency in English
(4) reside in one of the underserved, census-identified primarily African American communities in Buffalo, NY
(5) severe depression
(6) active suicidal intent
(7) DSM-V diagno...
Emergency department patients or adult companions of pediatric emergency department patients will take an anonymous survey. This survey will be used to determine the rate of Covid19 vaccinations in emergency rooms. Read More
Emergency Department patients or their adult companions
This study enrolls adults who have tested positive for COVID-19 and are currently hospitalized at Buffalo General Hospital or Millard Fillmore Hospital. The purpose is to learn whether immune study drugs that target inflammation can help with symptoms and recovery from COVID-19. 75% of the participants will receive study drug and 25% will receive placebo (no active ingredients). Neither the doctors or you will know which study drug or placebo you will receive. The study drug will either be : one time infliximab (Remicade) infusion in vein, one time abatacept (Orencia) infusion in vein, or 28 days of cenicriviroc (CVC) tablets. Most participants will also receive the anti-viral Remdesivir infusion in vein for maximum of 10 days. The study will last for about 60 days. Read More
Admitted to Buffalo General or Millard Fillmore Suburban or awaiting admission in the ED with symptoms suggestive of COVID-19.
Male or non-pregnant female adults ≥18 years of age at time of enrollment.
Has laboratory-confirmed (within 14 days prior to enrollment) SARS-CoV-2 infection as determined by PCR or other commercial or public health assay in any specimen.
We are doing this study to find out if there is a connection between poor sleep in children with cystic fibrosis and the development of diabetes. Cystic Fibrosis patient and the parent will complete a single 10 minute survey about how CF patient sleeps. The study team will collect some information about the child’s health including the results of an oral glucose tolerance test. Read More
Inclusion criteria include having cystic fibrosis, being 10 years old or older and either having an oral glucose tolerance test (a screen for CF-related diabetes) in 2020 or planning to have one in 2021. Exclusion criteria include a history of long-standing CF-related diabetes, liver failure or liver transplant or receipt of steroids within 6 weeks prior to the oral glucose tolerance test.
This sub-study is for Parkinson Disease (PD) patients enrolled in a previous lithium trial with Dr. Guttuso. The additional data from this sub-study may help bolster the current evidence that lithium positively affects blood biomarkers and support further research on lithium’s potential to slow PD progression. Read More
1. Diagnosed with PD according to the UK Brain Bank Criteria.23
2. 45-80 years of age.
3. Enrolled in the previous lithium trial.
4. No history of cardiac arrhythmias besides atrial fibrillation that is rate controlled.
5. No unstable cardiac, medical or psychiatric condition in the opinion of the PI.
6. No current use of illicit drugs or current alcohol abuse in the o...
This study is for COPD patients 40 years and older who have been hospitalized and discharged within 90 days. These patients will be interviewed and take a one-time survey which takes 30-45 minutes. Read More
1) Age ≥40 years
2) GOLD stage ≥2, FEV1 <80% predicted
3) Hospitalized for an acute exacerbation for COPD
4) Discharged from the hospital setting within 90 days of the AECOPD
Caregivers: We will ask COPD patients to identify caregivers who might also be willing to participate in the caregiver interviews. A caregiver will be defined as a family me...
This study enrolls men with prostate cancer. The purpose of this study is to compare using radium-223 and docetaxel chemotherapy treatment vs. using docetaxel alone in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Radium223 has been FDA approved to treat men with prostate cancer that has spread to the bone, but it has not been approved for men with cancer that has spread to soft tissue or in combination with the chemotherapy drug docetaxel. Read More
Adults ages 18+.
Males with progressive Metastatic Prostate Cancer.
Have 2+ bone lesions.
This study enrolls adults diagnosed with head and neck cancer who have plans to complete chemoradiotherapy. The purpose of this study is to learn the best timing for feeding tube placement and speech therapy to create the best quality of life for patients. Read More
Adults ages 18+.
Patients with Head and Neck Cancer being treated at ECMC and Cancer Care WNY.
Patients planning to receive concurrent chemo-radiation therapy.